[The treatment of chronic myeloleukemia with recombinant alfa-2 interferon].

A trial has been conducted of recombinant alpha 2-interferon (reaferon) used in 32 patients with Ph'[correction of Rh']-positive chronic myeloid leukemia (CML). A chronic stage was in 3, transient in 3 and blast in 1 patients. 25 CML patients were newly diagnosed.

[Detection of HTLV-I virus in patients with myeloproliferative hemoblastoses].

An association of HTLV-I virus with myelomonocytic leukemia was established by serologic and molecular-biologic procedures. Antibodies to one or two HTLV-I proteins were identified in 10 out of 30 patients with myelomonocytic leukemia; both antibodies to certain HTLV-I proteins and an integrated provirus were detected in 3 cases. Upon examination of donor blood, antibodies to one or two HTLV-I proteins were found in 0.

[A method for predicting the course of chronic myeloleukemia].

The effects of a synthetic prostaglandin E1 (PGE1) analog on colony-forming activity in agar cultures of peripheral blood and bone marrow was studied in 28 patients with chronic myeloid leukemia and 9 hematologically healthy subjects. Addition of PGE1 to normal bone marrow culture was followed by a significant drop in the number of colonies per dish in 8 out of the 9 subjects. In leukemic patients, the effect was bizarre.

[Chronic myelomonocytic leukemia].

Retrospective analysis of 23 cases of chronic myelomonocytic leukemia (CMML) was presented. Clinical findings, peripheral blood and bone marrow indices, ultrastructural, cytochemical, biochemical (the level of serum and urine lysozyme), cytogenetic investigations as well as the type of leukemic cell growth in culture (monolayer) were considered. Proceeding from the above analysis, the authors found it appropriate to attribute CMML to myelodysplasia.

FAB classification of chronic myelomonocytic leukemia: heterogeneity revealed on the basis of bone marrow findings.

We report on 12 patients who fulfilled the FAB diagnosis criteria of chronic myelomonocytic leukemia (CMML). Some clinical findings (splenomegaly) as well as biological parameters (WBC count, cellularity of bone marrow sections, presence of dyserythropoiesis in bone marrow smears) were subjected to particular analysis. This allowed the assignment of each patient onto one of three separate hematological syndromes: (1) RA or RAEB with monocytosis, (2) myelomonocytic dysplasia (a novel syndrome) and (3) true CMML.